AOA Dx & Prof. Uri Saragovi Awarded $100,000 CAD by the Canadian Institute of Health Research for the Development of Early Stage Ovarian Cancer Diagnostic

AOA Dx is proud to announce a $100,000 CAD award in collaboration with Prof. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University for further development of a proprietary liquid biopsy for diagnosis of early stage ovarian cancer.​

The funding will support ongoing development of AKRIVIS GD, a diagnostic test for ovarian cancer. The technology is based on novel method of quantifying tumor marker gangliosides in blood. This unique approach allows to diagnose ovarian cancer in early stages of the disease.

Proof of concept data shows that AKRIVIS GD has both an excellent sensitivity and specificity when compared to traditional diagnostic methods for early and late stage disease.

Prof. Saragovi has established that the markers originate in the cancer, are over-expressed in tumor cells and are stable non-mutating targets. These findings validate that the markers can diagnose both early and late-stage disease with excellent accuracy.

Ovarian cancer is the most lethal gynecologic cancer due to late diagnosis. Improving early stage diagnosis is fundamental to improving the 5 year survival rate. Recent studies have suggested that any improvements in test accuracy in the early stages can reduce the 5-year mortality rate by as much as 50%. An accurate early diagnosis test could save up to 100,000 women per year.​

“We are proud to see our research with Prof. Saragovi validated by the Canadian Institute of Health Research and remain committed to solving the challenge of early diagnosis of ovarian cancer. Women’s Health receives less than 10% of all funding so this is a great step in the right direction towards supporting innovation in this space” says Oriana Papin-Zoghbi, CEO at AOA Dx.

About AOA Dx Inc.
AOA Dx Inc (AOA Inc) is a US company, with teams based in Boston, New York and London developing cancer diagnostics in the field of women’s health. AOA Dx Inc, a female led company, is committed to bringing the first accurate early stage liquid biopsy ovarian cancer diagnostic test to market that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers. More information can be found at

Corporate Communications